Metvix (Methyl Aminolevulinate)

Methyl aminolevulinate is taken up by skin cells and converted inside the cell to protoporphyrin IX, a photosensitizer. When the area is illuminated with red light, protoporphyrin IX produces reactive oxygen species that selectively damage dysplastic keratinocytes, leading to lesion clearance while sparing normal tissue.

The prescribed amount of Metvix is determined by the treating physician based on the size and number of lesions, the treatment protocol, and the specific illumination device used. The prescriber decides the exact quantity to apply and the timing of light exposure for each patient.

The safety of Metvix during pregnancy or lactation has not been established, and the product’s pregnancy category is listed as unknown. Healthcare providers generally advise avoiding use unless the potential benefit justifies any possible risk to the fetus or infant.

To request Metvix, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Metvix offers a photodynamic approach that selectively destroys dysplastic cells, whereas other options such as cryotherapy, topical 5‑fluorouracil or imiquimod rely on freezing or immune modulation. Photodynamic therapy can provide precise lesion targeting with good cosmetic outcomes, but it requires a light‑activation step and specialized equipment.

Metvix should be stored at room temperature, below 25 °C, in its original packaging. Keep the container tightly closed, protect it from light and moisture, and avoid freezing. Handling should be performed with clean hands or gloves to prevent contamination of the cream.

A thin layer of Metvix cream is applied to the cleaned, dry lesion(s) by a qualified healthcare professional. After a defined incubation period (usually a few hours), the area is illuminated with a calibrated red‑light source. The treated skin is then monitored for the expected local reaction.

Serious risks include severe allergic reactions such as anaphylaxis, extensive skin ulceration, secondary infection, and rare but life‑threatening conditions like Stevens‑Johnson syndrome or toxic epidermal necrolysis. Patients should be instructed to seek immediate medical attention if they develop widespread rash, blistering, or systemic symptoms.

Metvix is contraindicated in individuals with known hypersensitivity to methyl aminolevulinate or any component of the formulation, in patients with active infections at the treatment site, and in those who are unable to avoid sunlight exposure during the post‑treatment period. Caution is also advised for patients with severe photosensitivity disorders.